Clinical Trial Update: Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cediranib maleate in patients with persistent, recurrent, or refractorily advanced ovarian epithelial, fallopian tube, or prim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Cediranib Maleate (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02